BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rosuvastatin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rosuvastatin\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07820891-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07820891)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Trial in Healthy Participants
  to Assess Drug Interaction Potential of BGB-43395\nEstimated primary comp
 letion: 22 November 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07820891
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550816-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07550816)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Drug-drug Interaction Study of 
 ZT002 Injection in Overweight and Obese Participants\nEstimated primary co
 mpletion: 5 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07550816
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982131-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT06982131)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Study Investigating the Safet
 y of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitav
 astatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Pa
 rticipants\nEstimated primary completion: 7 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06982131
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07378293-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07378293)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Effects of Selected Statins on 
 Blood Glucose Levels in Healthy Volunteers\nEstimated primary completion: 
 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ros
 uvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07378293
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389304-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07389304)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: [Effects of Selected Statins on
  Cardiovascular Parameters in Healthy Volunteers]\nEstimated primary compl
 etion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07389304
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804980-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT06804980)
DESCRIPTION:Rosuvastatin\, phase 4.\nStudy: DESIFOR-EXPAND (MHIF)\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06804980
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07534592-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07534592)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Study to Investigate the Effe
 ct of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participant
 s\nEstimated primary completion: 25 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07534592
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03169985-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT03169985)
DESCRIPTION:Rosuvastatin\, phase 4\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Randomized Controlled Trial of Moderate-Intensity Rosuvastatin W
 ith Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Pr
 ogression of Coronary Atherosclerotic Plaque\nEstimated primary completion
 : 28 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ro
 suvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03169985
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862621-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07862621)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Clinical Trial of MK-6916 Wit
 h Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)\nEstima
 ted primary completion: 9 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07862621
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372625-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07372625)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Study to Investigate the Effe
 cts of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin\,
  Rosuvastatin\, Repaglinide\, and Midazolam in Patients With Advanced Soli
 d Tumors Harboring a TP53 Y220C Mutation.\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastat
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7372625
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339722-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07339722)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Study of LY4515100 in Healthy
  Participants\nEstimated primary completion: March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07339722
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881224-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07881224)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Multiple-dose Study Investiga
 ting the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix i
 n Healthy Adult Subjects\nEstimated primary completion: 9 March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07881224
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939594-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07939594)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: An Evaluation of the Potential 
 for VH4011499 Drug-drug-interactions\nEstimated primary completion: 12 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079
 39594
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504198-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rosuvastatin: Phase 2/3 readout est. (NCT07504198)
DESCRIPTION:Rosuvastatin\, phase 2/3.\nStudy: Neuroprotection of Memantine 
 and Rosuvastatin\nEstimated primary completion: April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07504198
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748273-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Rosuvastatin: Phase na readout est. (NCT07748273)
DESCRIPTION:Rosuvastatin\, phase na.\nStudy: Rosuvastatin and Losartan Phar
 macokinetics After Bariatric Surgery\nEstimated primary completion: 15 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07748
 273
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholeste
 rolaemia\nEstimated primary completion: 28 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07619118
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912387-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT05912387)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Statin Therapy in Primary Scler
 osing Cholangitis (PSC): a Multi-omics Study\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuva
 statin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05912387
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05614739-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT05614739)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: FORAGER-1: A Study of Vepugrati
 nib (LY3866288\; LOXO-435) in Participants With Cancer With a Change in a 
 Gene Called FGFR3\nEstimated primary completion: June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05614739
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629999-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07629999)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Single and Multiple Dose Study 
 to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participa
 nts and Assessments of Food and pH Effects on Relative Bioavailability\, a
 nd Drug-Drug Interaction Potential in Healthy Participants\nEstimated prim
 ary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07629999
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850091-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT05850091)
DESCRIPTION:Rosuvastatin\, phase 4\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Polygenic Risk-based Detection of Subclinical Coronary Atheroscl
 erosis and Intervention With Statin and Colchicine\nEstimated primary comp
 letion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05850091
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04903223-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT04903223)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Liver Adiposity Effects on Pedi
 atric Statin\nEstimated primary completion: 30 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04903223
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538649-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT06538649)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Effect of Statins on Crohn's Di
 sease\nEstimated primary completion: 31 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06538649
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767345-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT06767345)
DESCRIPTION:Rosuvastatin\, phase 4\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-
 Intensity Statin for Coronary Plaque Stabilization\nEstimated primary comp
 letion: November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06767345
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488105-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rosuvastatin: Phase 2 readout est. (NCT06488105)
DESCRIPTION:Rosuvastatin\, phase 2\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Emergency Medicine Cardiovascular Risk Assessment for Lipid Diso
 rders Trial\nEstimated primary completion: 30 November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06488105
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460960-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rosuvastatin: Phase 2 readout est. (NCT07460960)
DESCRIPTION:Rosuvastatin\, phase 2.\nStudy: TRIal of STatin Therapy Effect 
 on Androgen Status and Erectile functioN in Men\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 osuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07460960
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04319627-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT04319627)
DESCRIPTION:Rosuvastatin\, phase 3.\nStudy: Statins for Venous Event Reduct
 ion in Patients With Venous Thromboembolism\nEstimated primary completion:
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuva
 statin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04319627
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254221-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280421
DTEND;VALUE=DATE:20280422
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT07254221)
DESCRIPTION:Rosuvastatin\, phase 4.\nStudy: Rosuvastatin for Prevention of 
 Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients\nEstim
 ated primary completion: 21 April 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07254221
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568574-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Rosuvastatin: Phase na readout est. (NCT07568574)
DESCRIPTION:Rosuvastatin\, phase na.\nStudy: Impact of Medically Supervised
  Performance-Enhancing Substances (PES) on Elite Athletes\nEstimated prima
 ry completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07568574
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05483010-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Rosuvastatin: Phase 2 readout est. (NCT05483010)
DESCRIPTION:Rosuvastatin\, phase 2.\nStudy: Statins in Patients With Clonal
  Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndrom
 es (MDS)\nEstimated primary completion: 31 May 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05483010
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474649-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07474649)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Pat
 ients Without Cardiovascular Events\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074746
 49
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736313-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07736313)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With St
 atin for ACS Patients\nEstimated primary completion: 1 September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07736313
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605130-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT07605130)
DESCRIPTION:Rosuvastatin\, phase 4.\nStudy: Efficacy and Safety Study of Di
 gital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strat
 egy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factoria
 l\, Randomized\, Parallel-Group\, Multicenter Trial\nEstimated primary com
 pletion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07605130
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912268-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07912268)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: Study of SIM0518 in Participant
 s With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: 1 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07912268
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744386-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Rosuvastatin: Phase 1 readout est. (NCT07744386)
DESCRIPTION:Rosuvastatin\, phase 1.\nStudy: A Study in Healthy Male Partici
 pants to Compare How CHF10196 Affects How the Body Absorbs and Processes T
 wo Commonly Used Medicines: Dabigatran\, a Blood Thinner\, and Rosuvastati
 n\, a Medicine Used to Lower Cholesterol\nEstimated primary completion: 15
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuv
 astatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07744386
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06186037-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT06186037)
DESCRIPTION:Rosuvastatin\, phase 4\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Comb
 ination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Mi
 nimal to Intermediate Coronary Artery Disease Without Percutaneous Coronar
 y Intervention\nEstimated primary completion: 28 February 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06186037
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05832229-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Rosuvastatin: Phase 2 readout est. (NCT05832229)
DESCRIPTION:Rosuvastatin\, phase 2.\nStudy: Liver Cirrhosis Network Rosuvas
 tatin Efficacy and Safety for Cirrhosis in the United States\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rosuvastatin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05832229
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799779-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT07799779)
DESCRIPTION:Rosuvastatin\, phase 4\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabil
 ization in Acute Coronary Syndrome\nEstimated primary completion: Septembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0779
 9779
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820086-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT06820086)
DESCRIPTION:Rosuvastatin\, phase 4.\nStudy: Polygenic Risk Driven Pragmatic
  Statin Trial for Heart Disease Prevention\nEstimated primary completion: 
 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvasta
 tin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06820086
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303816-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Rosuvastatin: Phase 4 readout est. (NCT07303816)
DESCRIPTION:Rosuvastatin\, phase 4.\nStudy: Statins to Prevent Cancer Assoc
 iated Blood Clots\nEstimated primary completion: 31 March 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07303816
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232069-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07232069)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: PRE-EMPT: Prospective RandomizEd Evaluation and Management of Pr
 emature aTherosclerosis\nEstimated primary completion: July 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07232069
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012629-5401@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07012629)
DESCRIPTION:Rosuvastatin\, phase 3.\nStudy: A EUROpean Randomized Study on 
 Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascu
 lar Events in People With Covert Brain Infarcts (CBI)\nEstimated primary c
 ompletion: 30 September 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rosuvastatin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07012629
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
